



**Pfizer New Zealand Limited**  
Level 10, 11 Britomart Place, Auckland 1010  
PO Box 3998, Shortland Street, Auckland 1140  
Tel: 09 354 3065 Fax: 09 374 7630

24 January 2023

Dear Healthcare Professional,

**Shelf life extension of PAXLOVID® (nirmatrelvir 150 mg/ritonavir 100 mg), film coated tablets, TT50-10969**

We would like to inform you that on 8 December 2022 an extension in shelf life for PAXLOVID has been approved in New Zealand by Medsafe.

The shelf life has been extended from 18 months to 24 months. The storage condition of 'Store below 25 degrees Celsius' remains unchanged.

This extension of the shelf life may be applied retrospectively to PAXLOVID batches manufactured prior to this approval. Cartons with an expiry date of January 2023 through to December 2023 printed on the carton or blisters may remain in use for a longer period beyond the printed expiry date, as long as the approved storage conditions have been maintained.

PAXLOVID is a co-packaged product consisting of nirmatrelvir and ritonavir tablets, which could have different production dates. For this reason, the updated expiry date cannot be calculated by adding 6 months or 12 months to the printed expiry date (that was determined based on the shelf life approved at the time of manufacturing) and must be determined by identifying the specific batch number in the list below:

<b><u>Batch Number</u></b>	<b><u>Printed Date</u></b>	<b><u>Updated Expiry Date</u></b>
FY6863	01/2023	09/2023
FY5905	01/2023	11/2023
FY9872	02/2023	09/2023
GA3992	02/2023	09/2023
GD8403	04/2023	02/2024
GD8408	04/2023	02/2024
GG2187	05/2023	03/2024
GJ2965	12/2023	03/2024
GJ2971	11/2023	03/2024
GJ7302	12/2023	03/2024

If you have stock to dispense that is labelled as expiring before its intended use, please refer to this table to apply an updated expiry as necessary.

Please note that you may continue to receive stock from the above batches and may need to continue to alter the expiry date for new stock. Please keep this notice with your PAXLOVID stock for future reference.



**PLEASE REVIEW THE CURRENT NEW ZEALAND DATA SHEET BEFORE PRESCRIBING OR DISPENSING.**

The New Zealand Data Sheet and Consumer Medicine Information can be found at <https://www.medsafe.govt.nz>.

**Adverse Event Reporting**

Healthcare professionals are asked to report any suspected adverse events at <https://nzphvc.otago.ac.nz/reporting/>. Alternatively, any adverse events which are experienced with PAXLOVID can be reported to Pfizer on 0800 736 363 or by email to [AUS.AEReporting@pfizer.com](mailto:AUS.AEReporting@pfizer.com).

**Medical Enquiries**

Please direct any medical enquiries to Medical Information via [www.pfizermedicalinformation.co.nz](http://www.pfizermedicalinformation.co.nz) or 0800 736 363.

Yours sincerely,



**Pasquale Gargiulo**  
Associate Medical Director  
Hospital Business Unit  
Pfizer New Zealand